Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's October Sprint Fidelis ICD lead recall resulted in a "one-time," $20 million bump up for St. Jude in the 2007 fourth quarter, contributing to $637 million in Q4 cardiac rhythm management sales, an increase of 19% from the prior-year period, St. Jude announced Jan. 23. The added revenue came almost entirely from Japan, where Medtronic did not get approval to market a Fidelis alternative until this month (1"The Gray Sheet" Oct. 22, 2007, p. 3). St. Jude exceeded $1 billion in total revenue in a single quarter for the first time in Q4, reporting $1.02 billion, up 18% from 2006. For the full year, the firm reported a 14% up tick to $3.78 billion, including double-digit growth in its CRM, atrial fibrillation and neuromodulation units

You may also be interested in...



Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude

Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall

Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead

Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel